Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT05433974Not ApplicableUnknown

Pre-therapeutic Analysis of the Individual Radiosensitivity of Cancer Patients in Luxembourg (APRI-Lux): Prospective National Interventional Study With Minimal Risk

Role: lead

NCT04948840Not ApplicableUnknown

Pilot Study of the Predictive Value of TREM1 Expression and Activation in Inflammation and Radio-induced Mammary Fibrosis

Role: lead

NCT03209128Terminated

Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala

Role: lead

NCT03199144Phase 2Withdrawn

Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer

Role: lead

NCT03206385Unknown

IMRT Followed by CyberKnife Boost Focused on the Gross Residual Pelvic Tumor Volume

Role: lead

NCT03235557Completed

CyberKnife for Prostate Cancer Patients Aged 70 y or More

Role: lead

NCT03286023Unknown

Stereotactic Radiotherapy for Brain Metastases

Role: lead

NCT03284151Unknown

Focused Stereotactic Radiation Treatment of Prostatic Adenocarcinoma

Role: lead

All 8 trials loaded